How Many Drugs for LUTS Due to BPH are Too Many?

Journal of Urology

Volumn 180, Issue 3, 2008, Pages 811-812

  Andersson, Karl Erik ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CETRORELIX; DOXAZOSIN; ELOCALCITOL; FINASTERIDE; GONADORELIN ANTAGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PLANT MEDICINAL PRODUCT; SILDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; TAMSULOSIN; TOLTERODINE; UNCLASSIFIED DRUG; VARDENAFIL; VITAMIN D3 AGONIST; YM 178;

ASTHMA; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; LOWER URINARY TRACT SYMPTOM; MALE SEXUAL DYSFUNCTION; MONOTHERAPY; ORGAN SIZE; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; TREATMENT OUTCOME;

ADRENERGIC ALPHA-ANTAGONISTS; BENZHYDRYL COMPOUNDS; CRESOLS; DOXAZOSIN; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; ERECTILE DYSFUNCTION; FINASTERIDE; HUMANS; IMIDAZOLES; MALE; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; PIPERAZINES; PROSTATIC HYPERPLASIA; SULFONAMIDES; SULFONES; TRIAZINES; URINATION DISORDERS;

EID: 48649088303     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.06.070     Document Type: Editorial

References (15)

1. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., et al., The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21 (2002) 167
2. Chapple C., Artibani W., Berges R., Kapkan S., Michel M., Perrin P., et al. New medical developments in the management of LUTS in adult men. World Health Organisation Report-Committee 6. In: McConnel J., Abrams P., Denis L., Khoury S., and Roehrborn C. (Eds). Male Lower Urinary Tract Dysfunction (2006), Health Publications Ltd, New Jersey 143-194
3. Gonzalez R.R., and Kaplan S.A. First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment?. World J Urol 24 (2006) 360
4. Marks L.S., Roehrborn C.G., and Andriole G.L. Prevention of benign prostatic hyperplasia disease. J Urol 176 (2006) 1299
5. Andersson K.E. LUTS treatment: future treatment options. Neurourol Urodyn 26 (2007) 934
6. McConnell J.D., Roehrborn C.G., Bautista O.M., Andriole Jr. G.L., Dixon C.M., Kusek J.W., et al., Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387
7. Baldwin K.C., Ginsberg P.C., Roehrborn C.G., and Harkaway R.C. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 58 (2001) 203
8. Barkin J., Guimarães M., Jacobi G., Pushkar D., Taylor S., and van Vierssen Trip O.B. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 44 (2003) 461
9. Kaplan S.A., Roehrborn C.G., Rovner E.S., Carlsson M., Bavendam T., and Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296 (2006) 2319
10. Yang Y., Zhao X.F., Li H.Z., Wang W., Zhang Y., Xiao H., et al. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl) 120 (2007) 370
11. McVary K.T., Monnig W., Camps Jr. J.L., Young J.M., Tseng L.J., and van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177 (2007) 1071
12. McVary K.T., Roehrborn C.G., Kaminetsky J.C., Auerbach S.M., Wachs B., Young J.M., et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177 (2007) 1401
13. Stief C.G., Porst H., Neuser D., Beneke M., and Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53 (2008) 1236
14. Kaplan S.A., Gonzalez R.R., and Te A.E. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51 (2007) 1717
15. Kloner R.A., Jackson G., Emmick J.T., Mitchell M.I., Bedding A., Warner M.R., et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 172 (2004) 1935